The clinical and biochemical evidence of MAS and gastrointestinal symptoms in our patients was similar to the original description of AIFEC.6, 10 Clinical symptoms and resistance to multiple immunomodulatory agents together with increased serum levels of free IL-18 prompted consideration of the diagnosis of AIFEC and a trial of IL-18BP in patient P1. Here, IL18 is linked to macrophage activation syndrome.